

**Annual Report**  
**Division of Clinical Epidemiology**  
**Department of Medicine - Jewish General Hospital**  
**January 1 - December 31, 2020**

**SUMMARY**

The 7 members of the Division received total funding of **\$18,752,245** in 2020, including **\$5,454,750** as principal investigators and **\$13,297,495** as co-investigators. They published a combined total of **127** peer-reviewed papers, with a large number of scientific presentations. Four of the members of the Division are supported by FRQS chercheur-boursier awards and the other three are recipients of endowed or James McGill Chairs. In 2020, the members supervised a combined 12 post-doctoral, 21 doctoral, 10 masters and 2 summer students. The Division members participated in extensive service to funding agencies, scientific journals and university departments.

**1. Research and publications:**

**Suissa, Samy**

Dr. Samy Suissa is the Principal Investigator of the Canadian Network on Observational Drug Effect Studies (CNODES), and oversees funding of \$17.5 million received from CIHR for this network. CNODES assembles the top pharmacoepidemiologists in the country and uses a collaborative, population-based approach, exploiting existing healthcare databases across the country and using sophisticated, cutting edge and powerful analytical methods to rapidly evaluate the risks and benefits of medications on the health of Canadians.

Dr. Suissa's research is in pharmacoepidemiology which involves studying the risks and benefits of medications at the within the population at large. He specializes in the exploitation of existing computerized health databases to rapidly evaluate these risks. He has developed, and published extensively on, new methods of data analysis and study design that allow more rapid and accurate assessments of drug safety. He has conducted pharmacoepidemiological studies of several medications used for the treatment of chronic diseases, including asthma and COPD, cardiovascular and rheumatic diseases, and women's health issues. He has lectured extensively throughout the world, and is the author of over 540 peer-reviewed research papers published in scientific journals.

**Azoulay, Laurent**

The year 2020 was a highly productive year, with 26 published studies. These include publications in top specialty journals, such as Diabetes Care, Circulation, Lancet Diabetes & Endocrinology. My team has also published in respected epidemiologic journals, such as Epidemiology and American Journal of Epidemiology. The most significant achievements include a study assessing the cardiovascular safety of aromatase inhibitors among women with breast cancer (Circulation) and two other studies assessing the impact of the weight loss induced by GLP-1 receptor agonists on the detection of breast cancer (Epidemiology) and the first study to determine whether SGLT-2 inhibitors are associated with a short-term increased risk of breast cancer (Diabetes Care).

Total dollar amount of secured grants and research funding from all sources: \$1,310,115; this includes a new 2020 CIHR grant awarded as PI (\$286,875).

**Douros, Antonios**

Dr. Douros obtained his FRQS Junior 1 Salary Support Award. He published 9 peer-reviewed

publications (5 as first or senior author), including 3 in top-tier journals (BMJ, Annals of Internal Medicine, Diabetes Care).

He led an international, multicenter study conducted by the Canadian Network for Observational Drug Effect Studies (CNODES) that investigated the risk of diabetic ketoacidosis with the newer antidiabetic drug class of sodium-glucose co-transporter-2 (SGLT-2) inhibitors. This has been an important safety concern since 2015 according to several regulatory agencies including Health Canada. The study showed an almost 3-fold increased risk of diabetic ketoacidosis associated with the use of SGLT-2 inhibitors (**Douros, Ann Intern Med [Impact Factor 21.317], 2020**). The study findings provide robust evidence regarding this potentially fatal adverse effect.

### **Filion, Kristian**

Dr. Filion was awarded six grants by the CIHR and one from McGill University in 2020:

1. A population-based assessment of pharmacological treatments for gestational diabetes. (Nominated Principal Investigator – Project Grant) - \$191,251/2 years
2. The utilization, safety, and effectiveness of periconceptional high-dose folic acid supplementation. (Principal Investigator - Project Grant) - \$233,324/3 years
3. Vaping safety: a knowledge synthesis. (Co-Investigator – Catalyst Grant) - \$99,984/1 year
4. Anticoagulant treatment and the risk of adverse outcomes among hospitalized COVID-19 patients. (Nominated Principal Investigator - MI4 Emergency COVID-19 Research Funding Program) - \$91,000/1 year
5. Youth and e-cigarettes: a knowledge synthesis. (Co-Investigator - Project Grant) - \$114,750/2 years
6. A personalized dynamic blood pressure control plan for cardiovascular disease prevention among patients with hypertension. (Nominated Principal Investigator – Project Grant) - \$191,250/2 years
7. Determining the association between thyroid hormone replacement therapy and cardiovascular risk and mortality among individuals with subclinical hypothyroidism. (Co-Investigator - Project Grant) - \$122,400/2 years

In 2020, Dr. Filion had 35 articles published or in press (12 as first or senior author). He has 17 submitted manuscripts (5 as first or senior). His 2020 publications include a first author manuscript in the *BMJ*, a senior authorship in the *Annals of Internal Medicine*, and a publication in *JAMA*. He also has a first author invited editorial in the *American Journal of Epidemiology*, a leading journal in the field.

### **Greenwood, Celia**

Dr. Greenwood was lead organizer of the annual conference of the International Genetic Epidemiology Society ([www.geneticepi.org/iges-2020](http://www.geneticepi.org/iges-2020)). It was originally planned for Hong Kong, then due to civil unrest we moved it to Seoul, South Korea, then due to COVID-19 we had to transfer to an online meeting.

Dr. Greenwood was awarded 2 grants as Principal Investigator or Co-PI and 2 grants as co-investigator in 2020:

1. MiCM Research Match: co-PI with P. Campeau. \$20,000/1 year.
2. Improving robust high-dimensional causal inference and prediction modelling. CANSSI Collaborative Research Team. \$199,600 /3 years. (Co-PI)
3. The effects of neuropsychiatric CNVs on the integrity of brain structure and connectivity. CIHR project grant. \$755,00/ 4 years. (Co-I)
4. Artificial intelligence to create equitable multi-ethnic polygenic risk scores that improve

clinical care. Canadian Institute of Health Research (CIHR) / Medical Research Council of the UK: Canada-UK Artificial Intelligence (AI) Initiative. £500,000/3 years. \$863,260.742 CAD (Co-I).

In 2020, she published 14 articles (4 as senior author).

### **Platt, Robert**

Dr. Platt is a principal investigator on 2 grants awarded by CIHR and 1 from NSERC. In 2020, He is also a co-investigator on 6 awarded grants by the CIHR and one from McGill University:

In 2020, Dr. Platt had **31** articles published or in press (7 as first or senior author), 3 of which in high-impact publications in top statistics journals with trainees as first author:

1. Coulombe J, Moodie EEM, **Platt RW**. Weighted regression analysis to correct for informative monitoring times and confounders in longitudinal studies. *Biometrics*. 2020 Apr 25. [Epub ahead of print]. PMID: 32333384
2. †Simoneau G, Moodie EEM, Azoulay L, **Platt RW**. Adaptive Treatment Strategies with Survival Outcomes: An Application to the Treatment of Type 2 Diabetes using a Large Observational Database. *Am J Epidemiol*. 2020 May 5;189(5):461-469. doi: 10.1093/aje/kwz272. PMID: 31903490
3. Simoneau G, Moodie EEM, Nijjar JS, **Platt RW**. Finite sample variance estimation for optimal dynamic treatment regimes of survival outcomes. *Stat Med*. 2020 Dec 20;39(29):4466-4479. PMID: 32929753

### **Renoux, Christel**

Dr. Renoux obtained Junior 2 Clinical and epidemiological science career award by le Fond de Recherche en Santé du Québec (FRSQ). She has secured grants and research funding from all sources of \$151,870

Dr. Renoux has developed a unique niche as a neuroepidemiologist and pharmaco-epidemiologist at the Lady Davis Institute (LDI). She has developed a research program focused on the study of the effectiveness and safety of drugs in neurological diseases and unintended neurological side effects of drugs, areas not previously targeted by the group. In addition, with her expertise in the use of data from the Clinical Practice Research Datalink (CPRD), Dr. Renoux has been a welcome addition to the CPRD Team of the Canadian Network for Observational Drug Effect Studies (CNODES), a pan-Canadian drug safety network funded by CIHR.

## **2. Teaching and learning (undergraduate and graduate):**

### **Suissa, Samy**

Dr. Samy Suissa leads the Pharmacoepidemiology Summer Program in the Department of Epidemiology and Biostatistics which holds 4 pharmacoepidemiology courses and 2 novel specialized courses and in which he himself teaches the Advanced Pharmacoepidemiology course. He is currently supervising or co-supervising 1 MSc student and 1 Post-doctoral fellow and 2 PhD students graduated in 2020.

### **Azoulay, Laurent**

Number of degrees awarded: 3 degrees awarded: 2 MSc and 1 PhD

I have been teaching Pharmacoepidemiologic Methods (EPIB-639) since 2017. Over the years, this 4-credit course has evolved to include intermediate to advanced pharmacoepidemiologic concepts. The laboratory component of the course allows students to program complex exposure definitions (e.g., time-varying exposures), performing risk set sampling, and experiment with case-only designs (e.g., case-crossover, case-time-control). I have received perfect teaching scores in 2020.

Despite the pandemic, my research team has been highly productive. Indeed, the majority (n=14) of my 2020 publications are studies led by my graduate students. I am proud of their achievement.

### **Douros, Antonios**

Dr. Antonios Douros has 2 degrees awarded (MD, Dr.med.). He is an Assistant Professor (Research) in the Department of Medicine (Division Clinical Epidemiology) and an Associate Member in the Department of Epidemiology, Biostatistics, and Occupational Health at McGill University. Dr. Douros taught the Small Group Sessions “Interpreting diagnostic tests” (2), “Principles of screening” (2), “Lung cancer, smoking, case-control and cohort studies”, “Cardiovascular disease and randomized controlled trials” (2), “Statistics for clinicians” in the M.D. C.M. Program. He was also responsible for the concept, syllabus, and teaching of the 1-credit course “EPIB 662 Pharmacological Basis of Pharmacoepidemiology” in the MSc and PhD Epidemiology Programs. Finally, he co-teaches the 2-credit course “EPIB 661 PE III: Advanced Pharmacoepidemiology” of the Summer Session in Epidemiology and Biostatistics however due to COVID-19 this course was canceled.

Dr. Douros is a member in 3 thesis committees at McGill (2 MSc, 1 PhD). He also recruited a MDCM student to work on one of his CIHR grants.

### **Filion, Kristian**

Dr. Kristian Filion teaches in the medical school and in the Department of Epidemiology, Biostatistics, and Occupational Health. In the Department of Epidemiology, Biostatistics, and Occupational Health, Dr. Filion was the instructor in the courses entitled “Knowledge Synthesis” (3 credits); “EPIB-677 - Systematic Reviews” (3 credits) and “EPIB-670 - Systematic Reviews” (2 credits). He was also the co-instructor for the course entitled “Critical Appraisal” (1 credit). He gave a 1-hour lecture to the first year medical students in Block C.

In 2020, Dr. Filion supervised 1 PhD Student, 2 MSc student in epidemiology, and 4 post-doctoral fellows.

He is a member of 3 doctoral students’ thesis committees.

### **Greenwood, Celia**

Dr. Greenwood was the instructor in the course “Statistical Concepts in Genetics and Genomics (HGEN677 -3 credits)”, she lectured in “Principals of Medical Genetics (HGEN617)” and co-taught a 2 hour lecture on “Computer Applications in Medicine”. She supervised 1 Postdoc + 1 more who transitioned to a research associate in her group in early 2020, 5 PhD students and 3 undergraduate summer students.

Awards won by her students include:

- 1 FRQS scholarship
- 1 previous PhD student had one of his papers selected as a highlight paper in genetic epidemiology for May 2020
- 1 postdoctoral fellow had a paper selected as “Best paper in 2019 in Genetic Epidemiology”; prize given in 2020

She is also memberships in 12 graduate advisory committees.

### **Platt, Robert**

Dr. Platt was awarded the Albert Boehringer I Chair in Pharmacoepidemiology in 2016 and Interim Chair in the department of Epidemiology, Biostatistics, and Occupational Health at McGill University in 2020. He is a Professor and a Senior Scientist, McGill University Health Centre Research Institute.

Dr. Platt is the instructor in the courses entitled “EPIB-710 – Causal Inference” (3 credits) and “BIOS-610 - Causal Inference in Biostatistics” (4 credits). He was also a guest lecturer in other McGill Epidemiology and Biostatistics courses: minimum 3 hrs/term.

In 2020, Dr. Platt supervised 6 PhD Students and 5 post-doctoral fellows.

He has been a member of more than 25 student thesis committees since 1996.

### **Renoux, Christel**

Dr. Renoux teaches Introduction to Pharmacoepidemiology (EPIB633) a one-week intensive summer course given at McGill University. She is also a guest lecturer in Pharmacoepidemiologic Methods (EPIB639) in the Department of Epidemiology, Biostatistics and Occupational Health. In addition, she is coordinates and teaches the “Fundamentals of Medicine and Dentistry of the MDCM” at McGill University for undergraduate students

Student Supervision in 2020:

- Dai T. Cao (MSc Epidemiology 2018-2020)
- Harika Dasari (MPH-Epidemiology - Harvard T.H. Chan School of Public Health) 2019-
- Kyle Johnson (PhD Epidemiology) 2019-
- Krishna Roy (MSc Epidemiology) 2019-
- Alvi Anan Rahman (PhD Epidemiology) 2018-
- Liliya Sinyavskaya (PhD candidate Sciences biomédicales – Université de Montréal) 2018-

## **3. Involvement in the community:**

### **Suissa, Samy**

#### **Internal**

- Member, LDI/McGill Assistant Professor Search Committee, Department of Psychiatry, Lady Davis Institute, Jewish General Hospital, McGill University, 2020-2021
- Chair, PhD Epidemiology Comprehensive Exam Committee, Department of Epidemiology and Biostatistics, McGill University, 2019-2020
- Member, LDI Scientific Director Search Committee, Lady Davis Institute, Jewish General Hospital, 2019-2020
- Member, Pharmacoepidemiology Program Ad-Hoc Committee, Department of Epidemiology and Biostatistics, McGill University, 2018-
- Member, Student Awards Ad-Hoc Committee, Department of Epidemiology and Biostatistics, McGill University, 2018-
- Member, Departmental Tenure Committee, Department of Epidemiology, Biostatistics, McGill University, 2016-

#### **External**

#### **Advisory Board Committee**

- Membre, Comité de Gouvernance de la Biobanque Québécoise de la COVID-19 2020-

- External Advisory Board Member, Pfizer Chief Medical Office 2020-
- Expert and Panelist, MORPHOSYS, Germany 2020
- Scientific Advisory Board Member, Panalgo, Boston MA 2020-
- Advisory Board Member, Seqirus (Healthcare Alliance Group) 2020
- Scientific Advisory Board Member, The Pierre Louis Institute of Epidemiology and Public Health, Université de la Sorbonne 2019-
- Member, Multi-Regional Clinical Trials Center, Proactive Safety Surveillance Project, Harvard University, 2019-
- Advisory Board Member, RCT DUPLICATE project, Brigham and Women's, Hospital, Harvard University, 2017-
- International Advisory Board Member, Unicancer, 2016-
- Member, Drug Safety and Effectiveness Network (DSEN) Interim Science Advisory Committee (ISAC), Canadian Institutes for Health Research, 2011-

#### **Reviewer Committee**

- Research Methodology, Policy & General Interest Faculty, Faculty of 1000 Medicine, 2020-
- Advisor, Editorial Board, Journal of Chronic Obstructive Pulmonary Disease, 2019-
- Member, Editorial Board, Rambam Maimonides Medical Journal, 2012-
- Statistician/Epidemiologist Reviewer, The Lancet Respiratory Medicine, 2012-
- Member, Editorial Board, Multidisciplinary Respiratory Medicine, 2011-
- International Advisory Board Member, Statistical Advisor, European Respiratory Journal 2007-

#### **Azoulay, Laurent**

- 2020- Council for International Organizations of Medical Sciences (CIOMS)  
Member  
Working Group XIII – Real-World Data and Real-World Evidence in Regulatory Decision-Making
- 2020 – Institut national d'excellence en santé et services sociaux (INESSS)  
Member, Advisory Committee  
Real-World evidence on lung cancer incidence and treatment in Quebec
- 2020 – Grant Review Committee Member, Population Health 1 Committee  
Canadian Institutes of Health Research
- 2020 Invited Media Interview  
Antihypertensives linked to reduced risk of colorectal cancer. Medscape Medical News. URL: <https://www.medscape.com/viewarticle/933438>
- 2019 – Canadian Network of Drug Effect Studies (CNODES)  
Project Lead  
Study: The use of hydrochlorothiazide and the risk of melanoma and non-melanoma skin cancer
- 2019 – Chair, Réseau québécois de recherche sur les médicaments – RQRM  
Pilot Project Grant Committee
- 2019 – Committee Member, Fonds de recherche du Québec – Santé.  
Bourses de formation postdoctorale.  
Comité: Santé publique, prévention et promotion de la santé, épidémiologie, soins et services de santé
- 2018 – Committee Member  
Pharmacoepidemiology Program Committee  
Department of Epidemiology, Biostatistics and Occupational Health  
McGill University

- 2017 – Chair, MSc Epidemiology Admissions Committee  
Department of Epidemiology, Biostatistics and Occupational Health  
McGill University
- 2017 – Associate Editor, Drug Safety Journal
- 2016 – MSc Epidemiology Program Advisor  
Department of Epidemiology, Biostatistics and Occupational Health  
McGill University
- 2016 – Committee Member  
Epidemiology Program Committee  
Department of Epidemiology, Biostatistics and Occupational Health  
McGill University
- 2015 – Task Force Committee Member  
Integrated Graduate Program in Oncology  
Responsible for the Population and Global Cancer Control Track
- 2009 – Chair and Member, Internal Grant Review Committees, Centre for Clinical  
Epidemiology, Jewish General Hospital

### **Douros, Antonios**

1. Lady Davis Institute Internal Grant Review Program: Review Committee Member (5)  
including Review Committee Chair (4)
2. Ad-hoc Reviewer for 34 peer-reviewed journals
3. Conferences:
  - Poster Session Judge
    - 16. Annual Student Research Day of the Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC (Apr 2020; 1 hour)
    - Drug-Drug Interactions Special Interest Group Spotlight Posters; 36. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, International Society for Pharmacoepidemiology (ISPE) [virtual congress] (Sep 2020; 2 hours)
  - Abstract Reviewer Judge
    - Mid-Year Meeting, International Society for Pharmacoepidemiology (ISPE), Orlando, FL [cancelled] (Apr 2020; 5 hours)
    - 36. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, International Society for Pharmacoepidemiology (ISPE) [virtual congress] (Sep 2020; 10 hours)

### **Filion, Kristian**

#### **Internal**

- Epidemiology PhD Program, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Advisor, 2020-Present
- Admissions Committee, Epidemiology PhD Program, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Chair, 2020-Present
- Lady Davis Institute/TD Studentship Review Committee, Lady Davis Institute, Montreal, Quebec, 2017-Present
- McGill Pharmacoepidemiology Working Group, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Faculty Co-Facilitator, 2017-Present
- Admissions Committee, Epidemiology PhD Program, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Member, 2017-2020

- Pharmacoepidemiology Option, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, PhD Advisor, 2016-Present
- Joint MD-PhD Program Advisory Committee, Faculty of Medicine, McGill University, Montreal, Quebec, Member, 2015-Present

#### **External**

- Scientific Advisory Committee, Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT) Initiative, Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard University, Member, 2019 - Present
- Permanent Scientific Committee for the Evaluation of Medications, *Institut national d'excellence en santé et en services sociaux* (INESSS), Member, 2018-Present
- Health Research Training A – PhD, Post-Doctoral Fellowships, Canadian Institutes of Health Research. 2018-2020
- Scientific Committee, AstraZeneca Chair in Respiratory Health, University of Montreal, Member, 2017-Present
- Scientific Advisory Committee, Drug Safety and Effectiveness Network, Member, 2017-Present
- Evaluating the Efficacy of E-Cigarette use for Smoking Cessation (E3) Trial Steering Committee, Member, 2014-Present
- Canadian Network for Observational Drug Effect Studies (CNODES) Steering Committee, Member, 2016-Present

#### **Greenwood, Celia**

- Chair & Organizer, 2020 annual meeting of the International Genetic Epidemiology Society, July 1-4, 2020 (although originally planned for Seoul, South Korea, took place online due to COVID-19).
- Graduate Program Director, PhD program in Quantitative Life Sciences, McGill University 2017-current 2017-2019 (Term 1); 2020-2022 (Term 2)
- Hiring committee: Assistant Professor in Precision Medicine through CERC in Genomic Medicine. 2020.
- Review of applications for Mackenzie Scholarships, 2020
- Mentoring of a junior faculty in Anesthesia (2019 – present).
- Committee assessing Graduate Statistics Education, Faculty of Medicine (2019 – present).
- Member of the Advisory Committee for the Possible Reappointment of the Dean of Graduate and Postdoctoral Studies, McGill University, April 2019 – April 2020.
- Neurohub Scientific Committee, 2018-present.
- McGill Initiative in Computational Medicine, Committee Member: 2017 – present.
- Chair of Education Subcommittee
- Graduate Program Director, Quantitative Life Sciences, McGill University: November 2016 – November 2019, renewed 2019 - 2022.
  - Member of the Program Executive Committee for QLS
  - Admissions committee for QLS
  - Fellowships and awards committee for QLS
- Associate Editor, *Frontiers in Statistical Genetics and Methodology*. September 2015 - present
- Associate Editor, *Heredity*, 2020 – present

#### **Platt, Robert**

- President, Statistical Society of Canada - 2019-20
- *Statistics in Medicine*: Associate Editor, 2013-2019; Editor-in-Chief, 2019-present
- *American Journal of Epidemiology*: Associate Editor, 2014-2018; Editor 2018-present
- Other editorial board memberships:

- Journal of Epidemiology and Community Health: Associate Editor, 2008-present
- International Journal of Biostatistics: Associate Editor, 2011-present
- Pharmacoepidemiology and Drug Safety, Editorial Board, 2016-present

#### **Renoux, Christel**

- 2020-2021 **Committee member**  
Bourses de formation postdoctorale Fonds de recherche du Québec – Santé (FRQS)
- 2020 **Peer-review Committee member**  
Cancer Research UK - Population Research Committee - Project Award
- 2019-2020 **Peer-review Committee member**  
Heart and Stroke foundation Scientific Review Committee – Grant in aid
- 2019-2020 **Coordinator**, Epidemiology Seminars - Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital
- 2018 – Member Scholarship, Critical Thinking and Knowledge Translation theme subcommittee of the MDCM program committee
- 2017 – **Member**, College of Reviewers. Canadian Institutes of Health Research (CIHR)
- 2016 – **Medical Teaching Unit Director** - Fundamental of Medicine. Epidemiology Teaching – Department of Epidemiology McGill University
- 2014 – **Student Research Committee member** - Faculty of Medicine, McGill University
- 2013 – **Chair and member**, internal grant review committees, Centre for Clinical Epidemiology, Jewish General Hospital
- 2013 – **Member**, International Society for Pharmacoepidemiology (ISPE)
- 2012 – **Member**, Clinical Practice Research Datalink (CPRD) Team, Canadian Network of Observational Drug Effects Studies (CNODES)

#### **4. Partnerships:**

##### **Suissa, Samy**

Dr. Suissa teaches a summer course on Pharmacoepidemiology and Drug Safety in Utrecht, Netherlands and continues research and training collaboration at Clalit Health and Maccabi Health in Israel. However, due to COVID-19, these courses were canceled in 2020.

##### **Douros, Antonios**

I initiated several international collaborations (University of Oldenburg, Germany; Institute for Applied Health Services Research, Germany; Democritus University of Thrace, Greece) and strengthened my ongoing collaboration with the Berlin Initiative Study (Charité – Universitätsmedizin Berlin, Germany).

##### **Platt, Robert**

Interim Chair, Department of Epidemiology, Biostatistics and Occupational Health McGill University, Montreal, Quebec; September 2020 to present

##### **Renoux, Christel**

Co-supervision of a PhD candidate in Sciences biomédicales – Université de Montréal.  
Co-supervision of a student in MPH-Epidemiology - Harvard T.H. Chan School of Public Health

#### **5. Milestones:**

N/A

## 6. New hires, promotions, and retirements

**Dr. Renoux** was appointed Associate Professor in the Department of Neurology and Neurosurgery, McGill University.

## 7. Honours, awards, and prizes:

### **Suissa, Samy**

Distinguished James McGill Professor, McGill University (2019-Present)

Fellow – Royal Society of Canada, Life Sciences Division of the Academy of Science (2018-Present)

Fellow – Distinction, Canadian Academy of Health Science (2013-Present)

### **Azoulay Laurent**

William Dawson Scholar Award, McGill University (2017-2022)

### **Filion, Kristian**

ISPE – Pharmacoepidemiology and Drug Safety Best Article Award 2019 (Honorable Mention)

(2020) Article: *Oh IS, Filion KB, Jeong HE, Shin JY. An empirical assessment of immeasurable time bias in the setting of nested case-control studies: statins and all-cause mortality among patients with heart failure. Pharmacoepidemiol Drug Saf 2019;28:1318-1327.*

William Dawson Scholar Award, McGill University (2018-2023)

Fellow of the American Heart Association (2012-Present)

### **Renoux, Christel**

Student Award - McAfee Award for submitted abstract at the International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE).

## 8. Fundraising:

N/A

## SECTION I - DIVISION STATUS UPDATE

### 1. Mission and objectives of the Division

The Division of Clinical Epidemiology was founded in 1992 as part of the creation of the network of clinical epidemiology units across all McGill teaching hospitals. Its mission is to improve the health of individuals and populations through clinical and epidemiological research. Specific research themes include **Clinical Epidemiology, Pharmacoepidemiology and Genetic Epidemiology.**

### 2. A nominative list of academic staff, their academic rank

Dr. Laurent Azoulay – Associate Professor - active

Dr. Antonios Douros – Assistant Professor - active

Dr. Kristian Filion – Associate Professor - active

Dr. Celia Greenwood – Professor – active

Dr. Robert Platt – Professor – active

Dr. Christel Renoux – Associate Professor – active

Dr. Samy Suissa – Professor - active

## **SECTION II - GRANTS, PUBLICATIONS, AND SERVICE OUTSIDE OF MCGILL**

### **1. Grants and awards received**

#### **Suissa, Samy**

Source: Alzheimer Society of Canada

Title: The infection hypothesis in the etiology of Alzheimer's disease: Infectious diseases burden and risk of Dementia

Amount/Year: \$99,948/2020-22

Role: Co-Investigator PI: Paul Brassard

Source: Canadian Institutes for Health Research

Title: Canadian Network for Observational Drug Effect Studies (CNODES)-renewal.

Amount/Year: \$17,500,000/2016-21

Role: Principal Investigator

Source: Canadian Institute for Health Research - Rapid Funding for Drug Safety and Effectiveness Network (DSEN) Targeted Research Grant.

Title: Expansion of the CDM to CNODES sites in British Columbia and Alberta

Amount/Year: \$131,695/2019-20

Role: Co-Principal Investigator

Source: Health Brains for Healthy Living, McGill University

Title: A personalized approach to depression care: Discovering adaptive treatment strategies

Amount/Year: \$65,847.50/2018-20

Role: Co-Investigator PI: Erica Moodie

Source: Canadian Institutes for Health Research

Title: Secondary Data Analysis for Cancer Prevention and Control. Onset of cancer after an IBD diagnosis: potential impact on screening Strategies.

Amount/Year: \$144,000/2018-20

Role: Co-Investigator PI: Paul Brassard

Source: Canadian Institute for Health Research, Foundation Scheme 2014

Title: Statistical Methods in Pharmacoepidemiology and Perinatal Epidemiology.

Amount/Year: \$1,071,717/2015-22

Role: Program Expert PI: Robert Platt

#### **Azoulay, Laurent**

Source: Alzheimer Society of Canada

Title: The infection hypothesis in the etiology of Alzheimer's disease: Infectious diseases burden and risk of Dementia

Amount/Year: \$99,948/2020-22

Role: Co-Investigator; PI: Paul Brassard

Source: Canadian Institutes of Health Research – Project Grant

Title: SGLT-2 Inhibitors and Early Bladder Cancer Events: An International Multi-Centre Study

Amount/Year: \$286,875/2020-22

Role: Principal Investigator

Source: Canadian Institutes of Health Research – Project Scheme Grant

Title: Achieving hepatitis C elimination in Canada; addressing the needs of the diverse groups at risk.

Amount/Year: \$1,197,225/2018-21

Role: Co- Investigator; PI: Christina Greenaway

Source: Canadian Institutes of Health Research – Foundation Scheme

Title: Cancer pharmacoepidemiology: A population-based assessment of the risks of prescription drugs in vulnerable populations

Amount/Year: \$1,023,240/2015-21

Role: Principal Investigator

**Douros, Antonios**

Source: Canada – Germany collaborative industrial R&D program (National Research Council of Canada & German Federal Ministry for Economic Affairs and Energy) - R&D Project

Title: AIR\_PTE - AI based risk prediction and treatment effect estimation based on health claims data

Amount/Year: \$1,167,311/2020-22

Role: Co-Investigator PI: Macadamian Software Design & Development Consultancy, DCC Risk Analytics GmbH, InGef - Institute for Applied Health Services Research

Source: McGill Interdisciplinary Initiative in Infection and Immunity - Emergency COVID-19 Research Funding

Title: Anticoagulant treatment and risk of adverse outcomes among hospitalized COVID-19 patients

Amount/Year: \$91,000/2020

Role: Co-Investigator PI: Kristian Filion

Source: Alzheimer Society of Canada

Title: The infection hypothesis in the etiology of Alzheimer's disease: Infectious diseases burden and risk of Dementia

Amount/Year: \$99,948/2020-22

Role: Co-Investigator PI: Paul Brassard

Source: Canadian Institutes of Health Research (CIHR) - Project Grant

Title: A personalized dynamic blood pressure control plan for cardiovascular disease prevention among patients with hypertension

Amount/Year: C\$191,250/2020-22

Role: Co-Investigator PI: Kristian Filion

Source: Canadian Institutes of Health Research (CIHR) - Project Grant

Title: Concomitant use of sulfonylureas with warfarin and the risk of severe hypoglycemia in patients with type 2 diabetes

Amount/Year: C\$149,176/2019-21

Role: Principal Investigator

Source: Canadian Institutes of Health Research (CIHR) - Project Grant

Title: Effectiveness and safety of direct oral anticoagulants in patients with non-valvular atrial fibrillation and liver disease

Amount/Year: C\$225,676/2019-22  
Role: Principal Investigator

Source: Lady Davis Institute for Medical Research - Research Grant  
Title: Drug effectiveness and safety in vulnerable populations  
Amount/Year: C\$30,000/2019-22  
Role: Principal Investigator

**Filion, Kristian**

Source: Canadian Institutes of Health Research.  
Title: A population-based assessment of pharmacological treatments for gestational diabetes. (Project Grant Competition)  
Amount/Year: \$191,251/2020-2022  
Role: Nominated Principal Investigator

Source: Canadian Institutes of Health Research.  
Title: The utilization, safety, and effectiveness of periconceptional high-dose folic acid supplementation. (Project Grant Competition)  
Amount/Year: \$233,324/2020-2023  
Role: Principal Investigator, NPI: Azar Mehrabadi PhD

Source: Canadian Institutes of Health Research.  
Title: Vaping safety: a knowledge synthesis. (Catalyst Grant Competition)  
Amount/Year: \$99,984/2020-2021  
Role: Co-Investigator, PI: Mark J. Eisenberg MD, MPH

Source: McGill University.  
Title: Anticoagulant treatment and the risk of adverse outcomes among hospitalized COVID-19 patients. (MI4 Emergency COVID-19 Research Funding Program)  
Amount/Year: \$91,000/2020  
Role: Nominated Principal Investigator

Source: Canadian Institutes of Health Research.  
Title: Youth and e-cigarettes: a knowledge synthesis. (Project Grant Competition)  
Amount/Year: \$114,750/2020-2022  
Role: Co-Investigator, PI: Mark J. Eisenberg MD, MPH

Source: Canadian Institutes of Health Research.  
Title: A personalized dynamic blood pressure control plan for cardiovascular disease prevention among patients with hypertension. (Project Grant Competition)  
Amount/Year: \$191,250/2020-2022  
Role: Nominated Principal Investigator

Source: Canadian Institutes of Health Research.  
Title: Determining the association between thyroid hormone replacement therapy and cardiovascular risk and mortality among individuals with subclinical hypothyroidism. (Project Grant Competition)  
Amount/Year: \$122,400/2020-2022  
Role: Co-Investigator, PI: Oriana Yu MD, MSc

Source: Canadian Institutes of Health Research.  
Title: Cannabis and impaired driving: a knowledge synthesis. (Project Grant Competition)  
Amount/Year: \$114,750/2019-2021  
Role: Co-Investigator, PI: Mark J. Eisenberg MD, MPH

Source: Canadian Institutes of Health Research.  
Title: Effectiveness and safety of direct oral anticoagulants in patients with non-valvular atrial fibrillation and liver disease (Project Grant Competition)  
Amount/Year: \$225,676/2019-2022  
Role: Co-Investigator, PI: Antonios Douros MD, PhD

Source: Canadian Institutes of Health Research.  
Title: Concomitant use of sulfonylureas with warfarin and the risk of severe hypoglycemia in patients with type 2 diabetes (Project Grant Competition)  
Amount/Year: \$149,176/2019-2021  
Role: Co-Investigator, PI: Antonios Douros MD, PhD

Source: Canadian Institutes of Health Research.  
Title: A systematic review of interventions for the opioid crisis: examining approaches in a Canadian context and vulnerable sub-populations (CIHR Operating Grant: Evaluation of Interventions to Address the Opioid Crisis)  
Amount/Year: \$99,970/2019-2020  
Role: Co-Investigator, PI: Mark J. Eisenberg MD MPH

Source: Canadian Institutes of Health Research.  
Title: Levothyroxine for the treatment of subclinical hypothyroidism in pregnancy: a population-based assessment (Project Grant Competition)  
Amount/Year: \$175,950/2018-2020  
Role: Principal Investigator

Source: Canadian Institutes of Health Research.  
Title: Evaluating the Efficacy of E-Cigarette use for Smoking Cessation (E3) Trial Extension (Project Grant Competition)  
Amount/Year: \$267,750/2018-2020  
Role: Co-Investigator, PI: Mark J. Eisenberg MD MPH

Source: Canadian Institutes of Health Research.  
Title: Canadian Network for Observational Drug Effect Studies (DSEN Collaborating Centre for Observational Studies)  
Amount/Year: \$17,500.00/2016-2021  
Role: Co-Investigator PIs: Samy Suissa PhD, Colin R. Dormuth ScD, David A. Henry MD, Robert W. Platt PhD, Ingrid Sketris PharmD

Source: Canadian Institutes of Health Research.  
Title: Improving long term outcomes after venous thromboembolism (VTE) (Foundation Scheme)  
Amount/Year: \$2,050,825/2015-2022  
Role: Project Expert PI: Susan Kahn MD MSc

**Greenwood, Celia**

Source: MiCM Research Match

Amount/Year: \$20,000/2020

Role: Co-Principal Investigator Co-PI: P. Campeau

Source: CANSSI Collaborative Research Team

Title: Improving robust high-dimensional causal inference and prediction modelling

Amount/Year: \$199,600/2021-24

Role: Co-Principal Investigator Co-PI: G. Cohen

Source: CIHR project grant.

Title: The effects of neuropsychiatric CNVs on the integrity of brain structure and connectivity.

Amount/Year: \$755,000/2020-24

Role: Co-Investigator PI: S. Jacquemont, D. Bzdok

Source: Canadian Institute of Health Research (CIHR) / Medical Research Council of the UK: Canada-UK Artificial Intelligence (AI) Initiative

Title: Artificial intelligence to create equitable multi-ethnic polygenic risk scores that improve clinical care.

Amount/Year: £500,000/2020-23 (\$863,260.742CDN)

Role: Co-Investigator PI: B. Richards, M. Inouye

Source: Cancer Research Society Operating Grant

Title: Susceptibility to immune-mediated colitis-associated colorectal cancer.

Amount/Year: \$120,000/2019-21

Role: Co-Investigator PI: N. Beauchemin

Source: HBHL Project Grant.

Title: Associating whole genome rare variants with brain structure and function

Amount/Year: \$200,000/2019-21

Role: Principal Investigator

Source: Natural Sciences and Engineering Discovery Grant.

Title: New directions in genetic association studies.

Amount/Year: \$150,000/2019-24

Role: Principal Investigator

Source: CIHR Project Grant.

Title: IMPACTT: A microbiome research core based on integrated microbiome platforms for advancing causation testing and translation.

Amount/Year: \$3,000.000/2019-24

Role: Co-Investigator PI: K. McCoy

Source: CIHR Project Grant.

Title: Estimating the effect size of rare genomic variants on cognitive and behavioural traits underlying neurodevelopmental disorders.

Amount/Year: \$1,335,000/2018-22

Role: Co-Principal Investigator PI: S. Jacquemont

Source: Bioinformatics and Computational Biology competition

Title: Precision medicine in cellular epigenomics.

Amount/Year: \$660,512/2018-21

Role: Co-Principal Investigator PI: K. Oualkacha

Source: CIHR Project Grant.

Title: Modeling gene expression trajectories in the human developing brain: applications to pediatric brain tumors.

Amount/Year: \$753,525/2018-23

Role: Co-Investigator PI: C. Kleinman

Source: Healthy Brains for Healthy Lives Discovery Fund for Interdisciplinary Research (McGill University)

Title: Integrative analytics for multi-model, multi-scale neuroscience.

Amount/Year: \$1,500,000/2018-21

Role: Co-Investigator PI: B. Misić

Source: CIHR Project grant.

Title: Developmental origins of childhood obesity: tracking the causal epigenetic changes programming adiposity in children.

Amount/Year: \$1,240,000/2017-22

Role: Co-Investigator

Source: Genome Canada, Genomics Technology Platforms: Operations Support and Technology Development Funds.

Title: McGill University and Génome Québec Innovation Centre.

Amount/Year: \$9,176,000/2017-22

Role: Co-Investigator PI: M Lathrop

Source: CIHR Project grant

Title: Innovative pre-clinical models to overcome drug resistance in triple negative breast cancer.

Amount/Year: \$952,425/2017-22

Role: Co-Investigator

Source: CIHR Team Grant: Developmental Origins of Health and Disease—Implications for Men, Women, Boys, and Girls.

Title: How the early environment interacts with prenatal adversity and genetic susceptibility to moderate the risk for anxious and depressive disorders.

Amount/Year: \$1,496,217/2016-21

Role: Co-Investigator PI: A. Wazana

Source: CIHR Project Grant

Title: The gender specific effects of prenatal adversity on the development of anxious and depressive psychopathology in early adolescence - the moderating effect of genes and early maternal care.

Amount/Year: \$1,227,024/2016-21

Role: Co-Investigator

### **Platt, Robert**

Source: Canadian Institutes of Health Research (CIHR) – Project Grant

Title: The utilization, safety, and effectiveness of periconceptional high-dose folic acid supplementation.

Amount/Year: \$233,324/2020-23

Role: Co-Investigator PI: Mehrabadi A

Source: Canadian Institutes of Health Research (CIHR) – Project Grant  
Title: A population-based assessment of pharmacological treatments for gestational diabetes  
Amount/Year: \$191,251/2020-22  
Role: Co-investigator PI: Kristian Filion

Source: Canadian Institutes of Health Research (CIHR) - Operating Grant: COVID-19 May 2020  
Rapid Research Funding Opportunity  
Title: PRevention of COVID-19 with Oral Vitamin D supplemental Therapy in Essential healthCare Teams (PROTECT)  
Amount/Year: \$ 4,224,996/2020-21  
Role: Co-investigator PI: Francine Ducharme

Source: McGill Interdisciplinary Initiative in Infection and Immunity (MI4)  
Title: Anticoagulant treatment and risk of adverse outcomes among hospitalized COVID-19 patients  
Amount/Year: \$91,000/2020  
Role: Co-investigator PI: Kristian Filion

Source: Canadian Institutes of Health Research (CIHR) - Project Scheme  
Title: The use of SGLT-2 inhibitors and the risk of bladder cancer in patients with type 2 diabetes: an international real-world study  
Amount/Year: \$286,875/2020-22  
Role: Co-investigator PI: Laurent Azoulay

Source: Canadian Institutes of Health Research (CIHR) - Project Scheme  
Title: Determining the association between thyroid hormone replacement therapy and cardiovascular risk and mortality among individuals with subclinical hypothyroidism.  
Amount/Year: \$122,400/2020-22  
Role: Co-investigator PI: Oriana Yu

Source: Canadian Institutes of Health Research (CIHR) - Project Scheme  
Title: A personalized dynamic blood pressure control plan for cardiovascular disease prevention among patients with hypertension.  
Amount/Year: \$191,250/2020-22  
Role: Co-investigator PI: Kristian Filion

Source: Canadian Institutes of Health Research (CIHR) - Project Scheme  
Title: Effectiveness and safety of direct oral anticoagulants in patients with non-valvular atrial fibrillation and liver disease  
Amount/Year: \$225,676/2019-2022  
Role: Co-investigator PI: Antonios Douros

Source: Canadian Institutes of Health Research (CIHR) - Project Scheme  
Title: Concomitant use of sulfonylureas with warfarin and the risk of severe hypoglycemia in patients with type 2 diabetes.  
Amount/Year: \$ 149,176/2019-2021  
Role: Co-investigator PI: Antonios Douros

Source: Canadian Institutes of Health Research (CIHR) - Project Scheme

Title: Scleroderma Support group Leader Education (SSLED) Program.

Amount/Year: \$330 000/2018-21

Role: Co-investigator PI: Brett Thombs

Source: Canadian Institutes of Health Research (CIHR)

Title: Optimizing Resource Allocation in the NICU to Improve Outcomes of Very Preterm Infants

Amount/Year: \$210,000/2018-21

Role: Co-Principal Investigator PI: M. Beltempo

Source: Canadian Institutes of Health Research (CIHR) - Project Grant

Title: Achieving hepatitis C elimination in Canada; addressing the needs of the diverse groups at risk.

Amount/Year: \$1,197,225/2017-2021

Role: Co-investigator PI: Christina Greenaway

Source: Natural Sciences and Engineering Research Council of Canada

Title: Statistical Methods for High-Dimensional Administrative Data

Amount/Year: \$150,000/2017-22

Role: Principal Investigator

Source: Canadian Institutes of Health Research. (Foundation Scheme)

Title: Statistical Methods in Pharmacoepidemiology and Perinatal Epidemiology

Amount/Year: \$ 1,071,721/2015-22

Role: Principal Investigator

Source: Canadian Institutes of Health Research (CIHR) – Other: DSEN Collaborating Center for Observational Studies (2016)

Title: Canadian Network for Observational Drug Effect Studies

Amount/Year: \$17,500.00/2016-21

Role: Co-Principal Investigator NPI: Samy Suissa

### **Renoux, Christel**

Source Alzheimer Society of Canada

Title: The infection hypothesis in the etiology of Alzheimer's disease: Infectious diseases burden and risk of Dementia.

Amount/Year: \$99,948/2020-22

Role: Co-investigator PI: Paul Brassard

Source: Canadian Institutes of Health Research (CIHR) - Project Scheme

Title: Determining the association between thyroid hormone replacement therapy and cardiovascular risk and mortality among individuals with subclinical hypothyroidism.

Amount/Year: \$122,400/2020-22

Role: Co-investigator PI: Oriana Yu

Source: Canadian Institutes of Health Research (CIHR) - Project Scheme

Title: Concomitant use of sulfonylureas with warfarin and the risk of severe hypoglycemia in patients with type 2 diabetes.

Amount/Year: \$ 149,176/2019-2021

Role: Co-investigator PI: Antonios Douros

Source: Canadian Institutes of Health Research (CIHR) - Project Scheme

Title: Effectiveness and safety of direct oral anticoagulants in patients with non-valvular atrial fibrillation and liver disease

Amount/Year: \$225,676/2019-2022

Role: Co-investigator PI: Antonios Douros

Source Heart and Stroke Foundation of Canada – Grant-in-aid

Title: «Anticoagulants oraux et prévention de la démence chez les patients atteints de fibrillation auriculaire: étude de cohorte en population générale»

Amount/Year: \$151,870/2019-21

Role: Principal Investigator

## 2. Scholarly works published in the 2020 calendar year:

### Suissa S

1. Tran T, Šterclová M, Mogulkoc N, Lewandowska K, Müller V, Hájková M, Kramer MR, Jovanović D, Tekavec-Trkanjec J, Studnicka M, Stoeva N, Hejduk K, Dušek L, **Suissa S**, Vašáková M; EMPIRE registry. The European multipartner IPF registry (EMPIRE) validating long-term prognostic factors in idiopathic pulmonary fibrosis. *Respir Res*. 2020 Jan;21(1):11. doi: 10.1186/s12931-019-1271-z
2. Sultana J, Trotta F, Addis A, Brown JS, Gil M, Menniti-Ippolito F, Milozzi F, **Suissa S**, Trifirò G. Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy. *Drug Saf. Drug Saf*. 2020 Jan;43(1):1-5.
3. Douros A, Dell'Aniello S, Yu OHY, **Suissa S**. Comparative cardiovascular and hypoglycemic safety of glimiperide in type 2 diabetes: A population-based cohort study. *Diabetes Obes Metab*. 2020 Feb;22(2):254-262.
4. **Suissa S**, Dell'Aniello S, Gonzalez AV, Ernst P. Inhaled corticosteroid use and the incidence of lung cancer in COPD *Eur Respir J*. 2020 Feb 20;55(2).
5. **Suissa S**. Improving the Efficiency of Randomized Trials: The DYNAGITO Example. *COPD*. 2020 Feb;17(1):4-6.
6. Khosrow-Khavar F\*, Filion KB, Bouganim N, **Suissa S**, Azoulay L. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study. *Circulation*. 2020 Feb 18;141(7):549-559.
7. Hudson M, Dell'Aniello S, Shen S, Simon TA, Ernst P, **Suissa S**. Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study. *Rheumatology (Oxford)*. 2020 Apr;59(4):820-827.
8. **Suissa S**, Dell'Aniello S, Ernst P. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice. *Chest*. 2020 Apr;157(4):846-855.
9. Franklin JM, Glynn RJ, **Suissa S**, Schneeweiss S. Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials. *Clin Pharmacol Ther*. 2020 Apr;107(4):735-737.
10. Chalmers JD, Laska IF, Franssen FME, Janssens W, Pavord I, Rigau D, McDonnell MJ, Roche N, Sin DD, Stolz D, **Suissa S**, Wedzicha J, Miravittles M. Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: A European Respiratory Society Guideline. *Eur Respir J*. 2020 June;55(5):2000351.
11. He N, Dell'Aniello S, Zhai S, **Suissa S**, Renoux C. Risk of Fracture in Patients with Nonvalvular Atrial Fibrillation Initiating Direct Oral Anticoagulants vs Vitamin K Antagonists. *Eur Heart J Cardiovasc Pharmacother*. 2020 Jul 28 (Epub ahead of print).

12. Giorgianni F\*, Ernst P, Dell'Aniello S, **Suissa S**, Renoux C. Beta 2 agonists and the incidence of Parkinson's disease. *Am J Epidemiol*. 2020 Aug;189(8):801-810.
13. **Suissa S**. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. PracticeUpdate website. Available at: <https://www.practiceupdate.com/content/comparative-effectiveness-of-glucose-lowering-drugs-for-type-2-diabetes/103923/65/8/1>. Accessed August 07, 2020.
14. Tran T, Assayag D, Ernst P, **Suissa S**. Effectiveness of proton pump inhibitor in idiopathic pulmonary fibrosis: a population-based cohort study. *Chest* 2020 Aug 31:S0012-3692(20)34310-5. (Epub ahead of print).
15. Khosrow-Khavar F, Filion KB, Bouganim N, **Suissa S**, Azoulay L. Response by Khosrow-Khavar et al to Letters Regarding Article, "Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study" *Circulation*. 2020 Sep 15;142(11):e158-e159.
16. Khosrow-Khavar F\*, Bouganim N, Filion KB, **Suissa S**, Azoulay L. Cardiotoxicity of Sequential Aromatase Inhibitors Use in Women with Breast Cancer. *Am J Epidemiol*. 2020 Oct;189(10):1086-1095.
17. Tran T, **Suissa S**. Comparing new-user cohort designs: The example of proton pump inhibitor effectiveness in idiopathic pulmonary fibrosis. *Am J. Epidemiol*. 2020 Oct 30kwaa242. doi:10.1093. Online ahead of print.
18. **Suissa S**, Dell'Aniello S. Time-related biases in pharmacoepidemiology. *Pharmacoepidemiol Drug Saf*. 2020;29(9):1101-1110.
19. Abrahams D, Hudson H, **Suissa S**. Statins and lower mortality rheumatic diseases: An effect of immortal time bias? *Semin Arthritis Rheum*. 2020 Dec 19;51(1):211-218.

#### **CNODES Publications**

20. Yu OHY, Dell'Aniello S, Shah BR, Brunetti VC, Daigle JM, Fralick M, Douros A, Hu N, Alessi-Severini S, Fisher A, Bugden SC, Ronksley PE, Filion KB, Ernst P, Lix LM; Canadian Network for Observational Drug Effect Studies (**CNODES**) Investigators. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study. *Diabetes Care*. 2020 Oct;43(10):2444-2452.
21. Filion KB, Lix LM, Yu OH, Dell'Aniello S, Douros A, Shah BR, St-Jean A, Fisher A, Tremblay E, Bugden SC, Alessi-Severini S, Ronksley PE, Hu N, Dormuth CR, Ernst P, Suissa S; Canadian Network for Observational Drug Effect Studies (**CNODES**) Investigators. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study *BMJ*. 2020 Sep 23;370:m3342. doi: 10.1136/bmj.m3342.
22. Durand M, Schnitzer ME, Pang M, Carney G, Eltonsy S, Filion KB, Fisher A, Jun M, Kuo IF, Matteau A, Paterson JM, Quail J, Renoux C; Canadian Network for Observational Drug Effect Studies (**CNODES**) Investigators. Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi-database cohort study with meta-analysis. *Br J Clin Pharmacol*. 2020 Nov 26. doi: 10.1111/bcp.14669. Epub ahead of print. PMID: 33242339.
23. Fisher A, Hudson M, Platt RW, Dormuth CR; Canadian Network for Observational Drug Effect Studies (**CNODES**) Investigators. Tofacitinib Persistence in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study. *J Rheumatol*. 2021 Jan 1;48(1):16-24. doi: 10.3899/jrheum.191252. Epub 2020 Oct 1. Erratum in: *J Rheumatol*. 2021 Jan 1;48(1):1-2. PMID: 33004534.
24. Fisher A, Fralick M, Filion KB, Dell'Aniello S, Douros A, Tremblay É, Shah BR, Ronksley PE, Alessi-Severini S, Hu N, Bugden SC, Ernst P, Lix LM; Canadian Network for Observational Drug Effect Studies (**CNODES**) Investigators. Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user

cohort study. *Diabetes Obes Metab*. 2020 Sep;22(9):1648-1658. doi: 10.1111/dom.14082. Epub 2020 Jun 4. PMID: 32383792.

25. Daneman N, Chateau D, Dahl M, Zhang J, Fisher A, Sketris IS, Quail J, Marra F, Ernst P, Bugden S; Canadian Network for Observational Drug Effect Studies (**CNODES**) Investigators. Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study. *Clin Microbiol Infect*. 2020 May;26(5):613-618. doi: 10.1016/j.cmi.2019.10.016. Epub 2019 Oct 23. PMID: 31655215.

#### **Letters to the Editor**

26. **Suissa S**, Ernst P. Response to Lipworth et al. Letter to the Editor. Observational data with inhaled corticosteroid/LABA-LAMA may not reflect current practice with single triple inhalers. *Chest* 2020 Apr;157(4):1045-1046.
27. **Suissa S**, Ernst P. Response to Wang et al. Letter to the Editor. Different ICS and the risk of pneumonia. *Chest* 2020 May;157(5):1395-1396.
28. Ripamonti E, Azoulay L, Abrahamowicz M, Platt RW, **Suissa S**. Letter to the Editor. Pioglitazone and bladder cancer: improving research methods. *Diab Med* 2020 May;37(5):898-899.
29. **Suissa S**, Ernst P. Avoiding immortal time bias in observational studies. Letter to the Editor. *Eur Respir J*. 2020;20:55(3).
30. **Suissa S**. Mortality in IMPACT: Confounded by Asthma? *AJRCCM* 2020 Sept;202(5):772-773.
31. **Suissa S**. Inhaled corticosteroid withdrawal in chronic obstructive pulmonary disease: Can IMPACT help? *Am J Respir Crit Care Med*. 2020 Nov;202(9):1202-1204.
32. **Suissa S**, Dell'Aniello S, Ernst P. Response to article Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice. *Chest*. 2020 Aug;158(2):832-833.

#### **Azoulay, Laurent**

(Underline Denotes Trainee under My Supervision)

1. Abrahami D, McDonald E, Schnitzer M, **Azoulay L**. Trends in Prescribing Patterns of Proton Pump Inhibitors Surrounding New Guidelines. *Ann Epidemiol*. 2021; 55: 24-26.
2. Cragg J, **Azoulay L**, Collins G, De Vera M, Etminan M, Lalji F, Gershon A, Guyatt G, Harrison M, Jutzeler C, Kassam R, Kendzerska T, Lynd L, Mansournia MA, Sadatsafavi M, Tong B, Warner F, Tremlett H. The Reporting of Observational Studies of drug Effectiveness and Safety: highlighting key gaps in existing guidelines. *Expert Opin Drug Saf*. 2021;20(1):1-8.
3. Suissa M, Yin H, Yu OHY, Wong SM, **Azoulay L**. Sodium-Glucose Co-Transporter 2 Inhibitors and the Short-Term Risk of Breast Cancer Among Women with Type 2 Diabetes. *Diabetes Care*. 2021;44(1): e9-e11.
4. Rouette J, Yin H, Pottegård A, Nirantharakumar K, **Azoulay L**. Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer. *Drug Saf*. 2021;44(2):245-254.
5. Abrahami D, Pradhan R, Yin H, Honig P, Baumfeld Andre E, **Azoulay L**. Use of real-world data to emulate a clinical trial and support regulatory decision-making: assessing the impact of temporality, comparator choice and methods of adjustment. *Clin Pharmacol Ther*. 2021;109(2):452-461.
6. Greenaway C, Greenwald ZR, Akaberi A, Song S, Passos-Castilho AM, Abou Chakra CN; Alabdulkarim B, Platt RW, **Azoulay L**, Brisson M, Quach C. Epidemiology of varicella among immigrants and non-immigrants in Quebec, Canada, before and after the introduction of childhood varicella vaccination: a retrospective cohort study. *Lancet Infect Dis*. 2021;21(1):116-126.

7. Abrahami D, MacDonald E, Schnitzer M, **Azoulay L**. Trends in Acid Suppressant Drug Prescriptions in Primary Care in the United Kingdom: A Population Based Cross Sectional Study. *BMJ Open*. 2020;10:e041529.
8. Garant A, Kavan P, Martin AG, **Azoulay L**, Vendrely V, Lavoie C, Vasilevsky CA, Boutros M, Faria J, Nghia Nguyen T, Ferland E, Des Groseilliers S, Cloutier AS, Diec H, Drolet S, Richard C, Batist G, Vuong T. Optimizing Treatment Sequencing of Chemotherapy for Patients with Rectal Cancer: the KIR Randomized Phase II Trial. *Radiother Oncol*. 2020;155:237-245.
9. Ayele HT, Reynier P, **Azoulay L**, Platt RW, Cabaussel J, Benayoun S, Filion KB. Trends in the pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study. *World J Urol*. 2020 Sep 9. [Epub ahead of print]
10. Abrahami D, Renoux C, Yin H, Fournier J-P, **Azoulay L**. The association between oral anticoagulants and cancer incidence among individuals with nonvalvular atrial fibrillation. *Thromb Haemost*. 2020;120(10):1384-1394.
11. Santella C, Rouette J, Brundage MD, Filion KB, **Azoulay L**. Androgen deprivation therapy for prostate cancer and the risk of bladder cancer: a systematic review of observational studies. *Urol Oncol*. 2020; S1078-1439(20)30183-6.
12. Gómez-Izquierdo J, Filion KB, Boivin JF, **Azoulay L**, Pollak M, Yu OHY. Subclinical Hypothyroidism and the Risk of Cancer Incidence and Cancer Mortality: A Systematic Review. *BMC Endocr Disord*. 2020;20(1):83.
13. Mattison D, Gravel C, Krewski D, **Azoulay L**, Hicks BM, Douros A. Direct oral anticoagulants and oesophageal disorders: A pharmacovigilance analysis. *Eur J Clin Pharmacol*. 2020;76(7):1045-1047.
14. Giorli G, Rouette J, Yin H, Lapi F, Simonetti M, Cricelli C, Pollak M, **Azoulay L**. Prediagnostic use of low-dose aspirin and risk of incident metastasis and all-cause mortality among patients with colorectal cancer. *Br J Clin Pharmacol*. 2020; 1-8.
15. Khosrow-Khavar F, Bouganin N, Filion KB, Suissa S, **Azoulay L**. Cardiotoxicity of Use of Sequential Aromatase Inhibitors in Women with Breast Cancer. *Am J Epidemiol*. 2020;189(10):1086-1095.
16. Santella C, Yin H, Hicks BM, Yu OHY, Bouganin N, **Azoulay L**. Weight-lowering Effects of Glucagon-like Peptide-1 Receptor Agonists and Detection of Breast Cancer Among Obese Women With Diabetes. *Epidemiology*. 2020;31(4):559-566.
17. Rouette J, Yin H, Yu OHY, Bouganin N, Platt RW, **Azoulay L**. Incretin-based drugs and the risk of lung cancer among individuals with type 2 diabetes: a population-based cohort study. *Diabet Med*. 2020;37(5):868-875.
18. Khosrow-Khavar F, Filion KB, Bouganin N, Suissa S, **Azoulay L**. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Post-Menopausal Women with Breast Cancer: Population-Based Cohort Study. *Circulation*. 2020;141(7):549-559.
19. Ripamonti E, **Azoulay L**, Abrahamowicz M, Platt RW, Suissa S. Pioglitazone and bladder cancer: improving research methods. *Diabet Med*. 2020;37(5):898-899.
20. Simoneau G, Moodie EEM, **Azoulay L**, Platt RW. Adaptive Treatment Strategies with Survival Outcomes: An Application to the Treatment of Type 2 Diabetes Using a Large Observational Database. *Am J Epidemiol*. 2020;189(5):461-469.
21. Pradhan R, Yin H, Yu OHY, **Azoulay L**. The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer among Patients with Type 2 Diabetes: A Population-Based Cohort Study *Drug Saf*. 2020;43(2): 103-110.
22. Baumfeld-Andre E, Reynolds R, Caubel P, **Azoulay L**, Dreyer NA. Trial Designs Using Real-World Data: The Changing Landscape of the Regulatory Approval Process. *Pharmacoepidemiol Drug Saf*. 2020;29(10):1201-12.

23. Pradhan R, Montastruc F, Rousseau V, Patorno E, **Azoulay L**. Exendin-based glucagon like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis. *Lancet Diab Endocrinol*. 2020;8(1):13-14.
24. Huang TY, Welch EC, Shinde MU, Platt RW, Filion KB, **Azoulay L**, Maro JC, Platt R, Toh S. Reproducing Protocol-based Studies Using Parameterizable Tools - Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks. *Clin Pharmacol Ther*. 2020;107(4):966-977.
25. Secrest MH, **Azoulay L**, Dahl M, Clemens KK, Durand M, Hu N, Targownik L, Turin TC, Dormuth CR, Filion KB. A population-based analysis of antidiabetic medications in four Canadian provinces: secular trends and prescribing patterns. *Pharmacoepidemiol Drug Saf*. 2020;29 Suppl 1:86-92.
26. Wu JW, **Azoulay L**, Huang A, Paterson M, Wu F, Secrest M, Filion KB. Identification of incident pancreatic cancer in Ontario administrative health data: A validation study. *Pharmacoepidemiol Drug Saf*. 2020;29 Suppl 1:78-85.

**URL address where the list of all publications for 2020 can be found:**

<https://pubmed.ncbi.nlm.nih.gov/?term=azoulay+l+2020&sort=date>

### **Douros, Antonios**

1. Mielke N, Huscher D, **Douros A**, Ebert N, Gaedeke J, van der Giet M, Kuhlmann M, Kurth T, Schaeffner E. "Self-reported medication in community dwelling older adults in Germany: results from the Berlin Initiative Study" *BMC Geriatr*. 2020 Jan; 20(1): 22. (IF: 3.077)
2. **Douros A**, Dell'Aniello S, Yu OH, Suissa S. "Comparative cardiovascular and hypoglycemic safety of glimepiride in type 2 diabetes: a population-based cohort study" *Diabetes Obes Metab*. 2020 Feb; 22(2): 254-262. (IF: 5.900)
3. Mattison D, Gravel C, Krewski D, Azoulay L, Hicks B, **Douros A**. "Direct oral anticoagulants and esophageal disorders: a pharmacovigilance analysis" *Eur J Clin Pharmacol*. 2020 Jul; 76(7): 1045-1047. (IF: 2.641)
4. Fisher A, Alessi-Severini S, Filion KB, Bugden SC, Dell'Aniello S, **Douros A**, Ernst P, Fralick M, Hu N, Ronksley PE, Shah BR, Tremblay E, Lix LM for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators "Sodium-glucose co-transporter 2 inhibitors and the risk for urosepsis - a multi-site prevalent new-user cohort study" *Diabetes Obes Metab*. 2020 Sep; 22(9): 1648-1658. (IF: 5.900)
5. **Douros A**, Lix LM, Fralick M, Dell'Aniello S, Shah BR, Ronksley PE, Tremblay E, Hu N, Alessi-Severini S, Fisher A, Bugden SC, Ernst P, Filion KB for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators "Sodium-glucose co-transporter-2 inhibitors and the risk for diabetic ketoacidosis: A multicenter cohort study" *Ann Intern Med*. 2020 Sep; 173(6): 417-425. (IF: 21.317)
6. Yu OHY, Alessi-Severini S, Brunetti V, Bugden SC, Dell'Aniello S, **Douros A**, Ernst P, Filion KB, Fisher A, Fralick M, Hu N, Ronksley PE, Shah BR, Tremblay E, Lix LM for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators "Sodium-glucose co-transporter 2 inhibitors and the risk of below-knee amputation: A multicenter observational study" *Diabetes Care*. 2020 Oct; 43(10): 2444-2452. (IF: 16.019)
7. Filion KB, Alessi-Severini S, Bugden SC, Dell'Aniello S, Dormuth C, **Douros A**, Ernst P, Fisher A, Hu N, Lix LM, Ronksley PE, Shah BR, St-Jean A, Suissa S, Tremblay E, Yu OHY for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators "SGLT2 inhibitors and the risk of major adverse cardiovascular events: A multi-database study using a prevalent new-user design" *BMJ*. 2020 Oct; 370: m3342. (IF: 30.223)

## **Filion, Kristian**

\*Denotes trainee supervised, \*\*Denotes trainee co-supervised, † Denotes shared first authorship.

1. \*Lefebvre C, Zappitelli M, Hindie J, Platt RW, **Filion KB**. Non-steroidal anti-inflammatory drugs in chronic kidney disease: a systematic review of prescription practices and use in primary care. *Clin Kid J* 2020;13:63-71.
2. \*\*†Lancione S, \*\*†Wade K, Windle SB, **Filion KB**, Thombs BD, Eisenberg MJ. Non-medical cannabis in North America: an overview of regulatory approaches. *Public Health* 2020;178:7-14.
3. Singh S, **Filion KB**, Abenhaim HA, Eisenberg MJ. Prevalence and outcomes of prenatal recreational cannabis use: a scoping review. *BJOG* 2020;127:8-16.
4. Lefebvre C, **Filion KB**, Reynier P, Platt RW, Zappitelli M. Primary care prescriptions of nephrotoxic medications in children with chronic kidney disease. *Clin J Am Soc Nephrol*. 2020;15:61-68.
5. Secrest MH, Platt RW, Dormuth CR, Chateau D, Targownik L, Nie R, Doyle CM, Dell'Aniello S, **Filion KB**. Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research. *Pharmacoepidemiol Drug Saf* 2020;29 (Suppl 1):26-34.
6. Eberg M, Platt RW, Reynier P, **Filion KB**. Estimation of high-dimensional propensity scores with multiple exposure levels. *Pharmacoepidemiol Drug Saf* 2020;29 (Suppl 1):53-60.
7. Secrest MH, Platt RW, Reynier P, Dormuth CR, Benedetti A, **Filion KB**. Multiple imputation for systematically missing confounders within a distributed data drug safety network: A simulation study and real-world example. *Pharmacoepidemiol Drug Saf* 2020;29 (Suppl 1):35-44.
8. Secrest MH, Azoulay L, Dahl M, Clemens KK, Durand M, Hu N, Targownik L, Turin TC, Dormuth CR, **Filion KB**. A population-based analysis of antidiabetic medications in four Canadian provinces: secular trends and prescribing patterns. *Pharmacoepidemiol Drug Saf* 2020;29 (Suppl 1):86-92.
9. \*Masarwa R, Platt RW, **Filion KB**. Acetaminophen use during pregnancy and the risk of attention deficit hyperactivity disorder: A causal association or bias? *Paediatr Perinat Epidemiol* 2020;34:309-317.
10. Khosrow-Khavar F, **Filion KB**, Bouganim N, Suissa S, Azoulay L. Aromatase inhibitors and the risk of cardiovascular outcomes in post-menopausal women with breast cancer: population-based cohort study. *Circulation* 2020;141:549-559.
11. \*Yu YH, **Filion KB**, Bodnar L, Brooks M, Platt RW, Himes K, Naimi A. Visualization tool of variable selection in bias-variance tradeoff for inverse probability weights. *Ann Epidemiol* 2020;41:56-59.
12. \*\*Taheri H, **Filion KB**, Windle S, Reynier P, Eisenberg MJ. Cholesteryl ester transfer protein inhibitors and cardiovascular outcomes: a systematic review and meta-analysis of randomized controlled trials. *Cardiol* 2020;145:163-177.
13. Graham EA, Deschenes SS, Khalil MN, Danna S, **Filion KB**, Schmitz N. Measures of depression and incident type 2 diabetes: a systematic review and meta-analysis. *J Affect Disord*. 2020; 265: 224-232.
14. Khosrow-Khavar F, Bouganim N, **Filion KB**, Suissa S, Azoulay L. Cardiotoxic effects of sequential aromatase inhibitors use in women with breast cancer. *Am J Epidemiol* 2020;189:1086-1095.
15. \*\*Levett JY, Windle SB, **Filion KB**, \*Brunetti VC, Eisenberg MJ. Meta-analysis of transcatheter versus surgical aortic valve replacement in low surgical risk patients. *Am J Cardiol* 2020;125:1230-1238.

16. Singh S, Windle SB, **Filion KB**, Thombs BD, O'Loughlin JL, Grad R, Eisenberg MJ. E-Cigarettes and Youth: Patterns of Use, Potential Harms, and Recommendations. *Prev Med* 2020 Feb 3:106009. doi: 10.1016/j.ypmed.2020.106009. [Epub ahead of print]
17. Hébert-Losier A, **Filion KB**, Windle SB, Eisenberg MJ. A randomized controlled trial evaluating the efficacy of e-cigarette use for smoking cessation in the general population: E3 Trial design. *Can J Cardiol Open* 2020;2:168-175.
18. Eisenberg MJ, Habib B, Alcaraz M, Thombs B, **Filion KB**. Bright light therapy for depressive symptoms in hospitalized cardiac patients: a randomized controlled pilot trial. *PLOS ONE* 2020;15: e0230839.
19. Santella C, Rouette J, Brundage MD, **Filion KB**, Azoulay L. Androgen deprivation therapy for prostate cancer and the risk of bladder cancer: a systematic review of observational studies. *Urol Oncol* 2020;38:816-825.
20. Fisher A, Fralick M, **Filion KB**, Dell'Aniello S, Douros A, Tremblay E, Shah BR, Ronksley PE, Alessi-Severini S, Hu N, Bugden SC, Ernst P, Lix LM for the **Canadian Network for Observational Drug Effect Studies (CNODES) Investigators**. Sodium glucose co-transport 2 inhibitors and the risk for urosepsis – a multi-site prevalent new-user cohort study. *Diabetes Obes Metab* 2020; 22:1648-1658.
21. Gómez-Izquierdo J, **Filion KB**, Boivin JF, Azoulay L, Pollak M, Yu O. Subclinical hypothyroidism and the risk of cancer incidence and cancer mortality: a systematic review. *BMC Endocr Disord* 2020;20:83. doi: 10.1186/s12902-020-00566-9.
22. \*\*Gravel CA, **Filion KB**, Reynier PM, Platt RW. Post-myocardial infarction statin exposure and the one-year risk of stroke: a modification to inverse propensity score weighting for the consistent estimation of marginal causal effects in the presence of outcome misclassification. *Epidemiol.* 2020; 31:880-888.
23. Douros A, Lix LM, Fralick M, Dell'Aniello S, Shah BR, Ronksley PE, Tremblay E, Hu N, Alessi-Severini S, Fisher A, Bugden SC, Ernst P, **Filion KB** for the **Canadian Network for Observational Drug Effect Studies (CNODES) Investigators**. Sodium-glucose co-transporter 2 inhibitors and the risk of diabetic ketoacidosis: A multicenter international cohort study. *Ann Intern Med* 2020;173:417-425.
24. Yu OHY, Dell'Aniello S, Shah BR, \*Brunetti VC, Daigle JM, Fralick M, Douros A, Hu N, Alessi-Severini S, Fisher A, Bugden SC, Ronksley PE, **Filion KB**, Ernst P, Lix LM, for the **Canadian Network for Observational Drug Effect Studies (CNODES) Investigators**. Sodium glucose co-transporter-2 inhibitors and the risk of below-knee amputation: a multicenter observational study. *Diabetes Care* 2020;43:2444-2452.
25. Jeong HE, Lee H, Shin HJ, Chloe YJ, **Filion KB**, Shin JY. Association between NSAIDs use and adverse clinical outcomes among adults hospitalized with COVID-19 in South Korea: A nationwide study. *Clin Infect Dis.* 2020 Jul 27:ciaa1056. doi: 10.1093/cid/ciaa1056. [Epub ahead of print]
26. Durand M, Schnitzer ME, Pang M, Carney G, Eltonsy S, **Filion KB**, Fisher A, Jun M, Kuo IF, Renoux C, Paterson JM, Quail J, Matteau A, for the **Canadian Network for Observational Drug Effect Studies (CNODES) Investigators**. Comparative effectiveness and safety of direct oral anticoagulants compared to vitamin K antagonists in non-valvular atrial fibrillation: a multi-center observational cohort study. *CMAJ Open* 2020; 8:E877-E886.
27. \*\*Levett JY, Windle SB, **Filion KB**, Cabaussel J, Eisenberg MJ. Meta-analysis of complete versus culprit-only revascularization in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease. *Am J Cardiol* 2020;135:40-49.
28. \*Ayele HT, Reynier P, Azoulay L, Platt RW, Cabaussel J, Benayoun S, **Filion KB**. Trends in the pharmacological treatment of benign prostatic hyperplasia in the United Kingdom from 1998 to 2016: a population-based cohort study. *World J Urol* 2020 Sep 9. doi: 10.1007/s00345-020-03429-z. Online ahead of print.

29. **Filion KB**, Lix LM, Yu OHY, Dell'Aniello S, Douros A, Shah BR, St-Jean A, Fisher A, Tremblay E, Bugden SC, Alessi-Severini S, Ronksley PE, Hu N, Dormuth CR, Ernst P, Suissa S for the **Canadian Network for Observational Drug Effect Studies (CNODES) Investigators**. SGLT2 inhibitors and the risk of major adverse cardiovascular events: a multi-database study using a prevalent new-user design. *BMJ* 2020;370:m3342.
30. Eisenberg MJ, Hébert-Losier A, Windle SB, Greenspoon T, Brandys T, Fulop T, Nguyen T, Elkouri S, Montigny M, Wilderman I, Bertrand OF, Bostwick JA, Abrahamson J, Lacasse Y, Pakhale S, Cabaussel J, **Filion KB** for the **E3 Investigators**. Efficacy and safety of e-cigarettes plus counseling vs counseling alone for smoking cessation: a randomized clinical trial. *JAMA*. 2020;324:1844-1854.
31. Oh IS, Baek YH, Jeong HE, **Filion KB**, \*Shin JY. Analytical approaches to minimizing immeasurable time bias in cohort studies. *Int J Epidemiol* 2020 Dec 25:dyaa251. doi: 10.1093/ije/dyaa251. Online ahead of print.
32. Jeong HE, Oh IS, Lee H, **Filion KB**, Shin JY. Assessment of methodological approaches to correct for immeasurable time bias in case-only designs. *J Clin Epidemiol* 2020 Nov 7;S0895-4356(20)31173-2. doi: 10.1016/j.jclinepi.2020.11.004. Online ahead of print.
33. Durand M, Schnitzer ME, Pang M, Carney G, Eltonsy S, **Filion KB**, Fisher A, Jun M, Kuo IF, Matteau A, Paterson JM, Quail J, Renoux C, **Canadian Network for Observational Drug Effect Studies (CNODES) Investigators**. Effectiveness and safety among direct oral anticoagulants in non-valvular atrial fibrillation: a multi-database cohort study with meta-analysis. *Br J Clin Pharmacol*. 2020 Nov 26. doi: 10.1111/bcp.14669. Online ahead of print.
34. Wennberg EAB, Lasry A, Windle SB, **Filion KB**, Thombs BD, Gore G, Fischer B, Eisenberg MJ. Non-medical cannabis use among Indigenous Canadians: a systematic review of prevalence and associated factors. *Int J Drug Policy* 2020 Dec 23;90:103081. doi: 10.1016/j.drugpo.2020.103081. Online ahead of print.
35. **Filion KB**, \*Yu YH. Invited commentary: The prevalent new user design in pharmacoepidemiology: challenges and opportunities. *Am J Epidemiol* 2020 Dec 22;kwaa284. doi: 10.1093/aje/kwaa284. Online ahead of print. (Invited Editorial)

### **Greenwood, Celia**

1. Toukara F, Lefebvre G, **Greenwood CMT**, Ouakacha K (2020) A flexible copula-based approach for the analysis of secondary phenotypes in ascertained samples. *Statistics in Medicine*. 39(5):517-543. doi: 10.1002/sim.8416.
2. Lu T, Forgetta V, HY Yu O, Mokry L, Gregory M, Thanassoulis G, **Greenwood CMT**, Richards JB. (2020) Polygenic Risk for Coronary Heart Disease acts through Atherosclerosis in Type 2 Diabetes. *Cardiovascular Diabetology* [IF: 5.95]. 2020 Jan 30;19(1):12. doi: 10.1186/s12933-020-0988-9.
3. Szekely E, Neumann A, Sallis H, Jolicoeur-Martineau A, Verhulst FC, Meaney MJ, Pearson RM, Levitan RD, Kennedy JL, Lydon JE, Steiner M, **Greenwood CMT**, Tiemeier H, Evans J, Wazana A.(2020) Maternal prenatal mood, pregnancy-specific worries and early child psychopathology: Findings from the DREAM BIG consortium. **Journal of the American Academy of Child and Adolescent Psychiatry**. 2020 Apr 8; 60(1), P186-197. doi: 10.1016/j.jaac.2020.02.017. NUARY 01, 2021
4. Bhatnagar SR, Yang Y, Lu T, Schurr E, Loredon-Osti JC, Forest M, Ouakacha K, **Greenwood CMT**.(2020) Simultaneous SNP selection and adjustment for population structure in high dimensional prediction models. **PLOS Genetics** 2020 May 4; 16(5):e1008766. doi: 10.1371/journal.pgen.1008766. eCollection 2020 May. [Selected as the May 2020 highlight paper by the IGES Communications Committee]

5. Jiang L, **Greenwood C**, Yao W, Li L. (2020). Bayesian Hyper-LASSO Classification for Feature Selection with Application to Endometrial Cancer RNA-seq Data. **Scientific Reports**. 2020 Jun 16;10(1):9747. doi: 10.1038/s41598-020-66466-z.
6. Crouse A, Schramm C, Emond-Rheault JG, Herod A, Kerhoas M, Rohde J, Gruenheid S, Kukavica-Ibrulj I, Boyle B, **Greenwood C**, Goodridge L, Garduno R, Levesque R, Malo D, Daigle F. (2020). Combining whole genome sequencing and multi-model phenotyping to identify genetic predictors of Salmonella virulence. **mSphere**. 2020 Jun 10;5(3):e00293-20. doi: 10.1128/mSphere.00293-20.
7. Zhao K, Ouakacha K, Lakhal-Chaieb L, Labbe A, Klein K, Ciampi A, Hudson M, Colmegna I, Pastinen T, Zhang T, Daley D, **Greenwood CMT**. A novel statistical method for modeling covariate effects in bisulfite sequencing derived measures of DNA methylation. **Biometrics**. 2020 May 21. doi: 10.1111/biom.13307. Online ahead of print.
8. Manousaki D, Forgetta V, Keller-Baruch J, Zhao K, **Greenwood CMT**, Mooser V, Bassett JHD, Leslie WD, Richards JB. A Polygenic Risk Score as a Risk Factor for Medication-Associated Fractures. **J Bone Miner Res** [IF 6.3]. 2020 Jun 8. doi: 10.1002/jbmr.4104. October 2020, 35 (10): 1935–1941.
9. V Forgetta, J Keller-Baruch, M Forest, A Durand, S Bhatnagar, JP Kemp, M Nethander, D Evans, JA Morris, DP Kiel, F Rivadeneira, H Johansson, NC Harvey, D Mellström, M Karlsson, C Cooper, DM Evans, R Clarke, JA Kanis, E Orwoll, EV McCloskey, C Ohlsson, J Pineau, WD Leslie, **CMT Greenwood**, JB Richards. (2020) Development of a Polygenic Risk Score to Improve Screening for Fracture Risk: A Genetic Risk Prediction Study. **PLoS Med** [IF:9.4]. 2020 Jul 2;17(7):e1003152. doi: 10.1371/journal.pmed.1003152. eCollection 2020 Jul.
10. Y Wang, JY Patrick Park, A Pacis, R Denroche, GH Jang, A Zhang, A Cuggia, C Domecq, J Monlong, M Raites-Gurevich, R Grant, A Borgida, S Holter, C Stossel, S Bu, M Masoomian, I Lungu, J Bartlett, J Wilson, ZH Gao, Y Riazalhosseini, J Asselah, N Bouganin, T Cabrera, LM Boucher, D Valenti, J Biagi, **C Greenwood**, P Polak, W Foulkes, T Golan, G O'Kane, S Fischer, J Knox, S Gallinger, G Zogopoulos. (2020) A preclinical trial and molecularly-annotated patient cohort identify predictive biomarkers in homologous recombination deficient pancreatic cancer. **Clinical Cancer Research** 26(20): 5462-5476. doi: 10.1158/1078-0432.CCR-20-1439.
11. Jiang L, Huguet G, Schramm C, Ciampi A, Main A, Passo C, JeanLouis M, Auger M, Schumann G, Porteous D, Jacquemont S, **Greenwood CMT**. (2020) Estimating the effects of copy-number variants on intelligence using hierarchical Bayesian models. **Genetic Epidemiology** 44(8): 825-840. doi: 10.1002/gepi.22344.
12. Lu T, Zhou S, Wu H, Forgetta V, **Greenwood CMT**, Richards JB. (2020) Individuals with common diseases, but with a low polygenic risk score could be prioritized for rare variant screening. **Genetics in Medicine** 2020 Oct 28. Doi:10.1038/s41436-020-01007-7 Online ahead of print.
13. Lin Y-C, Brooks JD, Bull SB, Gagnon F, **Greenwood CMT**, Hung RJ, Lawless J, Paterson A, Sun L, Strug LJ. (2020). Statistical power in COVID-19 case-control host genomic study design. **Genome Medicine** 12 (1): 1-8. doi: 10.1186/s13073-020-00818-2.
14. Barry A, Bhagwat N, Misic B, Poline JB, **Greenwood CMT** (2020). Asymmetric influence measure for high dimensional regression. **Communications in Statistics – Theory and Methods** 1-27. doi: 10.1080/03610926.2020.1841793.

### **Platt, Robert**

†Methodological articles. \*Supervised graduate student

1. †\*Yu YH, Filion KB, Bodnar LM, Brooks MM, **Platt RW**, Himes KP, Naimi AI. Visualization tool of variable selection in bias-variance tradeoff for inverse probability weights. *Ann Epidemiol*. 2020 Jan; 41:56-59. PMID: 31982245

2. †**Platt RW**, Platt R, Brown JS, Henry DA, Klungel OH, Suissa S. How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. *Pharmacoepidemiol Drug Saf.* 2020;29(S1)3–7. doi: 10.1002/pds.4722. PMID: 30648307
3. \*Secrest MH, **Platt RW**, Reynier P, Dormuth CR, Benedetti A, Filion KB. Multiple imputation for systematically missing confounders within a distributed data drug safety network: A simulation study and real-world example. *Pharmacoepidemiol Drug Saf.* 2020 Jan;29 Suppl 1:35-44. PMID: 31486165
4. **Platt RW**, Henry DA, Suissa S. The Canadian Network for Observational Drug Effect Studies (CNODES): Reflections on the first eight years, and a look to the future. *Pharmacoepidemiol Drug Saf.* 2020 Jan;29 Suppl 1:103-107. PMID: 31814201
5. \*Eberg M, **Platt RW**, Reynier P, Filion KB. Estimation of high-dimensional propensity scores with multiple exposure levels. *Pharmacoepidemiol Drug Saf.* 2020 Jan;29 Suppl 1:53-60. PMID: 31571347
6. \*Secrest MH, **Platt RW**, Dormuth CR, Chateau D, Targownik L, Nie R, Doyle CM, Dell'Aniello S, Filion KB. Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research. *Pharmacoepidemiol Drug Saf.* 2020 Jan;29 Suppl 1:26-34. PMID: 30628152
7. \*Lefebvre CE, Filion KB, Reynier P, **Platt RW**, Zappitelli M. Primary Care Prescriptions of Potentially Nephrotoxic Medications in Children with CKD. *Clin J Am Soc Nephrol.* 2020 Jan 7;15(1):61-68. PMID: 31831578
8. Levy AR, Xing S, Brunelli SM, Cooper K, Finkelstein FO, Germain MJ, Kimel M, **Platt RW**, Belozeroff V. Symptoms of Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: A Prospective Cohort Study. *Am J Kidney Dis.* 2020 Mar;75(3):373-383. PMID: 31629575
9. Lemon LS, Bodnar LM, Garrard W, Venkataramanan R, **Platt RW**, Marroquin OC, Caritis SN. Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. *Int J Epidemiol.* 2020 Apr 1;49(2):648-656. doi: 10.1093/ije/dyz255. PMID: 31860078
10. Huang TY, Welch EC, Shinde MU, **Platt RW**, Filion KB, Azoulay L, Maro JC, Platt R, Toh S. Reproducing Protocol-Based Studies Using Parameterizable Tools-Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks. *Clin Pharmacol Ther.* 2020 Apr;107(4):966-977. PMID: 31630391
11. Thombs BD, Levis AW, Azar M, Saadat N, Riehm KE, Sanchez TA, Chiovitti MJ, Rice DB, Levis B, Fedoruk C, Lyubenova A, Malo Vázquez de Lara AL, Kloda LA, Benedetti A, Shrier I, **Platt RW**, Kimmelman J. Group Sample Sizes in Non-Regulated Health Care Intervention Trials Described as Randomized Controlled Trials were Overly Similar. *J Clin Epidemiol.* 2020 Apr;120:8-16. PMID: 31866472
12. Coulombe J, Moodie EEM, **Platt RW**. Weighted regression analysis to correct for informative monitoring times and confounders in longitudinal studies. *Biometrics.* 2020 Apr 25. [Epub ahead of print]. PMID: 32333384
13. †\*Simoneau G, Moodie EEM, Azoulay L, **Platt RW**. Adaptive Treatment Strategies with Survival Outcomes: An Application to the Treatment of Type 2 Diabetes using a Large Observational Database. *Am J Epidemiol.* 2020 May 5;189(5):461-469. doi: 10.1093/aje/kwz272. PMID: 31903490
14. Rouette J, Yin H, Yu OHY, Bouganim N, **Platt RW**, Azoulay L. Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes. *Diabet Med.* 2020 May;37(5):868-875. PMID: 32124472

15. †\*Ripamonti E, Azoulay L, Abrahamowicz M, **Platt RW**, Suissa S. Pioglitazone and bladder cancer: improving research methods. *Diabet Med*. 2020 May;37(5):898-899.PMID: 31995846
16. †\*Masarwa R, **Platt RW**, Filion KB. Acetaminophen use during pregnancy and the risk of attention deficit hyperactivity disorder: A causal association or bias? *Paediatric and Perinatal Epidemiology*. 2020 May;34(3):309-317. PMID: 3191282
17. Su CL, **Platt RW**, Plante JF. Causal inference for recurrent event data using pseudo-observations. *Biostatistics*, 2020 May 20;kxaa020. doi: 10.1093/biostatistics/kxaa020. Epub Ahead of Print. PMID: 32432686
18. Hu JMY, Arbuckle TE, Janssen P, Lanphear BP, Braun JM, **Platt RW**, Chen A, Fraser WD, McCandless LC. Associations of Prenatal Urinary Phthalate Exposure With Preterm Birth: The Maternal-Infant Research on Environmental Chemicals (MIREC) Study. *Can J Public Health*. 2020 Jun;111(3):333-341. PMID: 32441020
19. Wall-Wieler E, Robakis TK, Lyell DJ, Masarwa R, **Platt RW**, Carmichael SL. Benzodiazepine use before conception and risk of ectopic pregnancy. *Hum Reprod*. 2020 Jul 1;35(7):1685-1692. doi: 10.1093/humrep/deaa082. PMID: 32485732
20. Samuel M, Batomen B, Rouette J, Kim J, **Platt RW**, Brophy JM, Kaufman JS. Evaluation of propensity score used in cardiovascular research: a cross-sectional survey and guidance document. *BMJ Open*. 2020 Aug 26;10(8):e036961. PMID: 32847911
21. Ayele HT, Reynier P, Azoulay L, **Platt RW**, Cabaussel J, Benayoun S, Filion KB. Trends in the pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study. *World J Urol*. 2020 Sep 9. doi: 10.1007/s00345-020-03429-z. Online ahead of print. PMID: 32909173
22. Piske M, Thomson T, Krebs E, Hongdikokkul N, Bruneau J, Greenland S, Gustafson P, Karim ME, McCandless LC, Maclure M, **Platt RW**, Siebert U, Socías ME, Tsui JI, Wood E, Nosyk B. Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. *BMJ Open*. 2020 Sep 9;10(9):e036102. PMID: 32912944
23. Ukah UV, Dayan N, Auger N, He S, **Platt RW**. Development and Internal Validation of a Model Predicting Premature Cardiovascular Disease Among Women With Hypertensive Disorders of Pregnancy: A Population-Based Study in Quebec, Canada. *J Am Heart Assoc*. 2020 Oct 20;9(20):e017328. PMID: 33054502
24. Gravel CA, Filion KB, Reynier PM, **Platt RW**. Postmyocardial Infarction Statin Exposure and the Risk of Stroke with Weighting for Outcome Misclassification. *Epidemiology*. 2020 Nov;31(6):880-888. PMID: 33003152
25. Ukah UV, **Platt RW**, Potter BJ, Paradis G, Dayan N, He S, Auger N. Obstetric Hemorrhage and Risk of Cardiovascular Disease After Three Decades: A Population-Based Cohort Study. *BJOG*. 2020 Nov; 127(12):1489-1497. PMID: 32418291
26. Leal LF, Grandi SM, Miranda VIA, Dal Pizzol TDS, **Platt RW**, Silveira MFD, Bertoldi AD. Hypertensive Disorders of Pregnancy and Medication Use in the 2015 Pelotas (Brazil) Birth Cohort Study. *Int J Environ Res Public Health*. 2020 Nov 18;17(22):8541. PMID: 33217917
27. Karim ME, Pellegrini F, **Platt RW**, Simoneau G, Rouette J, de Moor C. The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review. *Mult Scler*. 2020 Nov 12;doi: 10.1177/1352458520972557. Online ahead of print. PMID: 33179573
28. Schnitzer ME, **Platt RW**, Durand M. A tutorial on dealing with time-varying eligibility for treatment: Comparing the risk of major bleeding with DOACs versus warfarin. *Statistics in Medicine*. 2020 Dec 20;39(29):4538-4550. PMID: 32812276
29. Simoneau G, Moodie EEM, Nijjar JS, **Platt RW**. Finite sample variance estimation for optimal dynamic treatment regimes of survival outcomes. *Stat Med*. 2020 Dec 20;39(29):4466-4479. PMID: 32929753

30. Wall-Wieler E, Robakis TK, Cesta CE, Masarwa R, Lyell DJ, Liu C, **Platt RW**, Carmichael SL. Antidepressant Use Around Conception, Prepregnancy Depression, and Risk of Ectopic Pregnancy. *Can J Psychiatry*. 2020 Dec;65(12):845-853. PMID: 32436752
31. Longo C, Blais L, Brownwell M, Quail JM, Sadatsafavi M, Forget A, Turcot MA, Nie Y, Li W, Tavakoli H, Tan Q, Fan Y, **Platt RW**, Ducharme FM. Association between asthma control trajectories in preschoolers and disease remission. *Eur Respir J*. 2020 Dec 10;2001897. doi: 10.1183/13993003.01897-2020. Online ahead of print. PMID: 33303530

### **Renoux, Christel**

(Underline Denotes Trainee under My Supervision)

1. Durand M, Schnitzer M, Pang M, Carney G, Eltonsy S, Filion KB, Fisher A, Jun M, fan Kuo I, Matteau A, Paterson M, Quail J, **Renoux C**, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Effectiveness and Safety among Direct Oral Anticoagulants in Non Valvular Atrial Fibrillation: A Multi-Database Cohort Study with Meta-Analysis. *Br J Clin Pharmacol*. 2020; 1-13. doi: 10.1111/bcp.14669.
2. Coulombe J, Moodie E, Shortreed S, **Renoux C**. Can the risk of severe depression-related outcomes be reduced by tailoring the antidepressant therapy to patient characteristics. *Am J Epidemiol*. 2020 Dec 9:kwaa260. doi: 10.1093/aje/kwaa260. [Epub ahead of print]
3. Coulombe J, Moodie EEM, Shortreed SM, **Renoux C**. Response to: Baby Steps to a Learning Mental Health Care System: Can we do the Work? *Am J Epidemiol*. 2020 Dec 9:kwaa262. doi: 10.1093/aje/kwaa262. [Epub ahead of print].
4. He N, Dell'Aniello S, Zhai S, Suissa S, **Renoux C**. Risk of Fracture in Patients with Nonvalvular Atrial Fibrillation Initiating Direct Oral Anticoagulants vs Vitamin K Antagonists. *Eur Heart J Cardiovasc Pharmacother*. 2020 Jul 28; pvaa094. doi: 10.1093/ehjcvp/pvaa094. [Online ahead of print]
5. Durand M, Schnitzer M, MPang M, Carney G, Eltonsy S, Filion K, Fisher A, Jun M; Kuo IF, **Renoux C**, Paterson M, Quail J, Matteau A. Comparative Effectiveness and Safety of Direct Oral Anticoagulants compared to vitamin K antagonists in Non-Valvular Atrial Fibrillation: A Multi-center Observational Cohort Study. *CMAJ open* 2020 Dec 18;8(4):E877-E886. doi:10.9778/cmajo.20200055.
6. Leshem R, Bar-Oz B, Diav-Citrin O, Gbaly S, Soliman J, **Renoux C**, Matok I. Selective serotonin reuptake inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) During Pregnancy and the Risk for Autism spectrum disorder (ASD) and Attention deficit hyperactivity disorder (ADHD) in the Offspring: a True Effect or a Bias? A Systematic Review & Meta-Analysis. *Reprod Toxicol*. 2020 Oct;97:3. doi: 10.1016/j.reprotox.2020.04.008.
7. Abrahami D, **Renoux C**, Yin H, Fournier J-P, Azoulay L. The association between oral anticoagulants and cancer incidence among individuals with nonvalvular atrial fibrillation. *Thromb Haemost*. 2020 Oct;120(10):1384-1394. doi: 10.1055/s-0040-1714213.
8. Douros A, Boivin JF, **Renoux C**. Author response: Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: A cohort study. *Neurology*. 2020 Aug 4;95(5):232. doi: 10.1212/WNL.0000000000010066.
9. Guertin J, Conombo B, Langevin R, Bergeron F, Holbrook A, Humphries B, Matteau A, Potter B, **Renoux C**, Tarride JE, Durand M. A systematic review of methods used for confounding adjustment in observational economic evaluations in Cardiology conducted between 2013 and 2017. *Med Decis Making* 2020 Jul;40(5):582-595. doi: 10.1177/0272989X20937257.
10. Sultana J, Giorgianni F, Scondotto G, Ientile V, Cananzi P, Leoni O, Pollina Addario S.W., De Sarro G, De Francesco A, Puzo, M.P., **Renoux C**, Trifirò G. Association between aflibercept and serious non-ocular haemorrhage compared to ranibizumab: a multi-centre

observational cohort study. *Drug Saf.* 2020 Sep;43(9):943-952. doi: 10.1007/s40264-020-00956-x.

11. Puzhko S, Schuster T, Barnet T, **Renoux C**, Rosenberg R, Bartlett G. Evaluating prevalence and patterns of prescribing medications for depression for patients with obesity using large primary care data (Canadian Primary Care Sentinel Surveillance Network). *Frontiers in Nutrition* 2020 Mar 17;7:24. doi: 10.3389/fnut.2020.00024. eCollection 2020.
12. Giorgianni E, Ernst P, Dell’Aniello S, Suissa S, **Renoux C**. Beta 2 agonists and the incidence of Parkinson’s disease. *Am J Epidemiol* 2020 Aug 1;189(8):801-810. doi: 10.1093/aje/kwaa012.
13. Puzhko S, Aboushawareb S, Kudrina I, Schuster T, Rosenberg R, Barnet T, **Renoux C**, Bartlett G. Excess body weight as a predictor of response to treatment with antidepressants in patients with depressive disorder. *Journal of Affective Disorders*. 2020 Apr 15;267:153-170. doi: 10.1016/j.jad.2020.01.113.
14. Doyle C, Lix L, Hemmelgarn B, Paterson M, **Renoux C**. Data variability across Canadian administrative health databases: differences in content, coding, and completeness. *Pharmacoepidemiol Drug Saf* 2020 Jan; 29 Suppl 1:68-77. doi: 10.1002/pds.4889.
15. Pacheco-Paez T, Montastruc F, Rousseau V, Chebane L, Lapeyre-Mestre M, **Renoux C**, Montastruc JL. Reply to: Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiological study". *Mov Disord.* 2020 Feb;35(2):376-377. doi: 10.1002/mds.27956.
16. Pacheco-Paez T, Montastruc F, Rousseau V, Chebane L, Lapeyre-Mestre M, **Renoux C**, Jean-Louis Montastruc JL. Parkinsonism associated with Gabapentinoid drugs: a pharmacoepidemiological study. *Movement Disorders* 2020 35 (1), 176-180. doi: 1035.1002/mds.27876.

**URL address where the list of all publications for 2020 can be found:**

<https://pubmed.ncbi.nlm.nih.gov/?term=Renoux+Christel+2020&sort=date&size=20>

### **3. Academic and community engagement service outside of McGill by individual members of the unit**

**Same as SUMMARY Section 3 Involvement in the Community**

Submitted by:

Samy Suissa, PhD  
Chief, Division of Clinical Epidemiology